Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of Part 1 of this study is to determine the maximally tolerated dose of
OPC-108459 in patients with paroxysmal and persistent atrial fibrillation (AF).
The purpose of Part 2 of this study is to determine potential efficacy of dose(s) of
OPC-108459 for the treatment of paroxysmal and persistent atrial fibrillation.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.